

North Central Cancer Treatment Group

N054C; Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients with Metastatic Colorectal Cancer

Status Change – September 11, 2009

NOTICE OF STATUS CHANGE

This study is reopening to patient accrual effective Friday, September 11, 2009 along with the activation of Addendum 3. The addendum contains revisions to the adverse event stopping rules in Section 16.62.

Please retain this notice with the protocol.